BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16103502)

  • 1. Health Canada lukewarm on Vioxx panel findings.
    Murray S
    CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
    [No Abstract]   [Full Text] [Related]  

  • 2. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 3. [Really only Vioxx?].
    Heinzl S
    Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
    [No Abstract]   [Full Text] [Related]  

  • 4. Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
    Can Fam Physician; 2005 Feb; 51(2):212-3. PubMed ID: 15751564
    [No Abstract]   [Full Text] [Related]  

  • 5. [The rise and fall of Vioxx: society, values and their choice].
    Caspi D
    Harefuah; 2004 Nov; 143(11):770-1. PubMed ID: 15603261
    [No Abstract]   [Full Text] [Related]  

  • 6. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 7. Balancing risks and benefits in pain medicine: wither Vioxx.
    Gallagher RM
    Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
    [No Abstract]   [Full Text] [Related]  

  • 8. The lessons of Vioxx--drug safety and sales.
    Waxman HA
    N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
    [No Abstract]   [Full Text] [Related]  

  • 9. Vioxx should be allowed back on the market advises expert panel.
    Sibbald B
    CMAJ; 2006 Aug; 175(3):234. PubMed ID: 16880435
    [No Abstract]   [Full Text] [Related]  

  • 10. Don't throw out the baby with the bathwater!
    Kamen B; Kieran M
    J Pediatr Hematol Oncol; 2005 Feb; 27(2):59-60. PubMed ID: 15701976
    [No Abstract]   [Full Text] [Related]  

  • 11. Vioxx award good news for Canadian lawsuits.
    Eggertson L
    CMAJ; 2005 Sep; 173(7):744. PubMed ID: 16186576
    [No Abstract]   [Full Text] [Related]  

  • 12. [VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
    Jerie P
    Cas Lek Cesk; 2005; 144(1):4. PubMed ID: 15789774
    [No Abstract]   [Full Text] [Related]  

  • 13. What happened to the coxibs on the way to the cardiologist?
    Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
    [No Abstract]   [Full Text] [Related]  

  • 14. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 15. Merck VIOXX "warning" is questioned.
    Allen TS; Henderson JH
    Tex Med; 2005 May; 101(5):5-6. PubMed ID: 15948521
    [No Abstract]   [Full Text] [Related]  

  • 16. New use approved for Vioxx.
    FDA Consum; 2002; 36(4):3. PubMed ID: 12184302
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 18. COX-2 inhibitors and hypercoagulability.
    Farkouh ME
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):35-6. PubMed ID: 16166966
    [No Abstract]   [Full Text] [Related]  

  • 19. Causation, Vioxx, and legal issues.
    Green MD
    Science; 2005 Nov; 310(5750):973. PubMed ID: 16284163
    [No Abstract]   [Full Text] [Related]  

  • 20. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.